Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Rhythm Biosciences Ltd has made significant advancements with its 2nd Generation ColoSTAT® diagnostic kit, showcasing superior performance for detecting colorectal cancer. The company is expanding its diagnostic portfolio with a focus on lung cancer, while also exploring potential applications in gastric cancer diagnostics. Recent corporate changes include the appointment of Dr. David Atkins as Managing Director, alongside board retirements, signaling a strategic renewal process.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.